Core Insights - IN8bio, Inc. has announced the addition of The Ohio State University as a new clinical site for its ongoing Phase 1 trial of INB-100, a gamma-delta T cell therapy for leukemia patients undergoing haploidentical stem cell transplantation [1][2] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases [4] - The lead program, INB-100, targets acute myeloid leukemia and evaluates haplo-matched allogeneic gamma-delta T cells administered post-hematopoietic stem cell transplant [4] Clinical Trial Details - The Phase 1 trial aims to assess the safety, durability, and anti-leukemic activity of INB-100 in the post-transplant setting [3] - Principal Investigator Dr. Joseph P. McGuirk leads the trial, which has shown encouraging long-term survival outcomes compared to historical data [3] - The trial has reported immune reconstitution, including the expansion and persistence of INB-100 gamma-delta T cells up to one year post-treatment, and an absence of severe graft-versus-host disease [3] Strategic Partnerships - The collaboration with The Ohio State University reflects strong interest in INB-100 and aims to accelerate enrollment in the Phase 1 trial [2] - The trial is expected to provide follow-up data next year, with multiple patients showing long-term leukemic remissions beyond four to five years [3]

Core Insights - IN8bio, Inc. is advancing innovative gamma-delta T cell therapies for cancer patients, focusing on unmet medical needs and aiming for "Cancer Zero" [2] - The company reported significant clinical progress, particularly with its INB-100 and INB-600 platforms, showcasing promising data in treating various cancers [5][6] Financial Highlights - For Q1 2025, IN8bio reported a net loss of $5.6 million, or $0.07 per share, an improvement from a net loss of $8.6 million, or $0.20 per share, in Q1 2024 [17][21] - Research and Development (R&D) expenses decreased to $3.0 million from $4.9 million year-over-year, while General and Administrative (G&A) expenses fell to $2.7 million from $3.7 million [14][21] - As of March 31, 2025, the company had cash of $11.9 million, down from $13.0 million a year earlier [17] Clinical Developments - INB-100 demonstrated a 100% relapse-free rate in treated Acute Myeloid Leukemia (AML) patients with a median follow-up of 20.1 months [5][6] - The INB-600 platform showed strong preclinical data, indicating potential applications in both oncology and autoimmune diseases, with lead candidates targeting CD19 and CD33 [6][12] Upcoming Milestones - IN8bio plans to present updated clinical data for INB-200 at the ASCO 2025 Annual Meeting on May 30, 2025 [9] - The company will also present at the ISCT 2025 Annual Meeting and the ASGCT 2025 Annual Meeting, highlighting advancements in gamma-delta T cell therapies [10][12] Corporate Strategy - IN8bio is focused on expanding its pipeline with the INB-600 gamma-delta T cell engager platform, which aims to enhance immune surveillance and reduce safety risks associated with conventional therapies [2][3] - The company is committed to operational execution and achieving meaningful data milestones to support its clinical programs [5][6]